about
Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous diseaseAIDS presenting with cutaneous Kaposi's sarcoma and bacillary angiomatosis in the bone marrow mimicking Kaposi's sarcoma.T-cell large granular lymphocyte leukemia associated with myelodysplastic syndrome: a clinicopathologic study of nine cases.Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features.Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).Metastatic splenic angiosarcoma presenting with thrombocytopenia and bone marrow fibrosis mimicking idiopathic thrombocytopenic purpura and primary myelofibrosis: a diagnostic challenge.Systemic mast cell disease presenting with peripheral blood eosinophilia.Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemiaPure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification.Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD componentsVariable expression of human myeloid specific nuclear antigen MNDA in monocyte lineage cells in atherosclerosis.Diagnostic value of GLUT-1 immunoreactivity to distinguish benign from malignant cystic squamous lesions of the head and neck in fine-needle aspiration biopsy material.Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyPatients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr8p11 myeloproliferative syndrome: a review.Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far.Gastrointestinal Kaposi sarcoma with appendiceal involvement.Peripheral T-cell lymphoma with a regulatory T-cell phenotype: report of a nodal and an extranodal case from Peru.Extranodal NK/T-cell lymphoma, nasal type, arising in association with saline breast implant: expanding the spectrum of breast implant-associated lymphomas.Follicular lymphoma with leukemic phase at diagnosis: a series of seven cases and review of the literature.Metastases to the breast from extramammary malignancies - PET/CT findings.Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients.Extranodal marginal zone lymphoma from ocular adnexae with subcutaneous involvement.Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis.Human papillomavirus-58 and -73-associated digital squamous cell carcinoma in a patient with aggressive digital papillary adenocarcinoma.Utility of quantitative flow cytometry immunophenotypic analysis of CD5 expression in small B-cell neoplasms.Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase.Large B-cell lymphoma arising in cardiac myxoma or intracardiac fibrinous mass: a localized lymphoma usually associated with Epstein-Barr virus?Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma.Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase.EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases.Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy.Iatrogenic immunodeficiency-associated classical hodgkin lymphoma: clinicopathologic features of 54 cases reported in the literature.
P50
Q28282623-5E60EE64-08EA-43DA-8B17-86BE99087D5AQ33346199-416CF9B9-A0E6-440F-918B-B4D108CF48E3Q33383361-B76137A3-38C4-423B-B774-29B486AA986DQ33391237-E0E6A54D-3A19-4187-BEE6-A1955AA8CC46Q33405526-E0F7F278-67C6-41F8-9D84-56CD14BA268EQ33408634-8E759F81-A270-4EB6-83FC-1CBB51163F9FQ33491631-A84D5BC9-CE90-4466-8658-9F1AA628C074Q33583294-4F7518B1-9150-40B3-B695-251E4BF345E2Q34106849-7781513C-F969-4C8A-85CE-9E20C96A61D5Q34151502-6C2473A6-BE69-41EB-9AC2-4F0EA46A471DQ34293927-73F4DE97-CD1F-4E02-9806-B7F46FC4B4A2Q34300709-BD4C01B2-B8E6-403D-87E8-20E4A928544AQ34404763-99DEE991-9414-4C2C-9CB7-D962348A03ABQ35910616-72215B36-69D1-47C1-A5F3-CDABCDEDBFC4Q36395599-6144F0CC-21CC-43D8-8356-5F9E533FC871Q36579119-86E8FA8F-D710-4CAB-9F29-DBB260945C83Q36979534-0E99AD43-16EF-4AB1-BE40-9636A2C9CC9FQ37006876-DD84A0EC-BD77-4672-BAA6-D5C7A5C5FE34Q37708608-7E6EF6FC-53C3-42B6-A63B-1D38EF23C4BCQ37826599-F2E47126-C765-467D-89B0-3D2B19D420EBQ37878807-DB9ACD9D-C01B-4379-A598-31DCEFB5AE32Q37916156-0177EAE9-8017-4E64-B271-18E13F993134Q38052779-5D9D9BDB-AA0E-4ECC-98A6-AE28B1FF9126Q38116141-3DD6A51E-DE85-44C9-8514-7E16B5A1B3D0Q38213148-59CAF1F0-BDF8-4194-AE5D-1F106A9BB90BQ38235161-4B465C80-353B-42B3-B1CA-F6E60B04967DQ38252626-24E0BE28-23BC-4337-AA4D-AAE99EFE9A19Q39283981-4996FE03-7F3B-45D5-A53E-0F1F7B734341Q39753901-7C36578E-60A5-46D1-A0C5-397DEA0330E7Q39885800-38A75F77-3514-406E-AEF9-C86755B4861BQ41578682-C7260E8F-C8BB-4E0A-B034-17F518EA8F5AQ42011284-52C18689-58B9-4C2F-BF8B-3EED6AAEDB9CQ42183849-56DD6805-54A4-482D-87A0-A04A6FA16E22Q42217211-E343F1E1-2331-4027-AF46-C0266CA0E059Q42774116-CE617C35-D0E6-4EC6-8D99-E2ADD6AA46F6Q43790916-FB173894-1CFD-4A51-9A0C-E44B6400D598Q44685328-8B9EBCD7-0C36-4D18-B7DA-4368F6DC2E3DQ45108139-883F229E-3003-40AB-A6FD-B87BFE87484BQ45358273-81016E57-65B9-4F29-A1F8-4FCB7F41F30BQ46115932-3BCD32F5-9524-46DE-AC28-256664529C42
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roberto N Miranda
@nl
Roberto N Miranda
@sl
Roberto N. Miranda
@en
Roberto N. Miranda
@es
type
label
Roberto N Miranda
@nl
Roberto N Miranda
@sl
Roberto N. Miranda
@en
Roberto N. Miranda
@es
prefLabel
Roberto N Miranda
@nl
Roberto N Miranda
@sl
Roberto N. Miranda
@en
Roberto N. Miranda
@es
P106
P1153
7102042110
P21
P31
P496
0000-0002-8467-5464